What is the appropriate management for a patient with asymmetric septal hypertrophy, severely reduced left ventricular systolic function, segmental wall‑motion abnormality, and an inferior wall that is hypokinetic?

This Patient Does NOT Have Typical Hypertrophic Cardiomyopathy—Urgent Coronary Evaluation is Required

The combination of asymmetric septal hypertrophy with severely reduced LV systolic function and a segmental wall motion abnormality (inferior hypokinesis) is highly atypical for HCM and strongly suggests an alternative diagnosis, most likely coronary artery disease with myocardial infarction. You must immediately evaluate for acute coronary syndrome and other HCM mimics before considering this as true HCM.

Why This Presentation is Atypical

Classic HCM presents with hyperdynamic LV systolic function, not severely reduced function 1. The 2024 AHA/ACC HCM guidelines explicitly state that HCM is characterized by LVH in the absence of another cardiac disease capable of producing the magnitude of hypertrophy evident 1. Your patient's presentation violates this fundamental principle.

The presence of:

• Severely reduced LV systolic function (not hyperdynamic)
• Segmental wall motion abnormality (inferior hypokinesis)
• Asymmetric septal hypertrophy

This triad suggests either:

1. Acute myocardial infarction (most likely)
2. Infiltrative cardiomyopathy (cardiac sarcoidosis, amyloidosis, Fabry disease)
3. End-stage HCM with systolic dysfunction (rare, but possible)

Immediate Management Steps

1. Rule Out Acute Coronary Syndrome

• Obtain serial troponins and ECG immediately
• Check for ST-segment changes, Q waves, or T-wave inversions in inferior leads
• The inferior wall hypokinesis suggests possible right coronary artery or left circumflex territory infarction
• Emergent coronary angiography if troponins elevated or ECG changes present

2. Evaluate for HCM Mimics

The 2024 guidelines emphasize that several conditions can mimic HCM 1:

Infiltrative diseases to exclude:

• Cardiac sarcoidosis: Can present with asymmetric septal hypertrophy, complete heart block, and segmental wall motion abnormalities 2. Consider PET-CT and cardiac MRI with late gadolinium enhancement
• Cardiac amyloidosis: Check serum/urine protein electrophoresis, free light chains, and cardiac MRI
• Fabry disease: Particularly in younger patients; check alpha-galactosidase A levels
• Glycogen storage diseases: Especially in children/young adults

Key diagnostic test:

• Cardiac MRI with late gadolinium enhancement is essential to:
  • Characterize tissue (edema, fibrosis, infiltration)
  • Assess for myocardial infarction pattern
  • Identify infiltrative disease patterns
  • Distinguish true HCM from mimics

3. If Coronary Disease and Mimics Excluded

Only after ruling out the above should you consider this as HCM with atypical features:

Assess for end-stage HCM:

• End-stage HCM with systolic dysfunction occurs in <5% of HCM patients
• Characterized by LV wall thinning, cavity dilation, and reduced ejection fraction
• The segmental nature of dysfunction (isolated inferior hypokinesis) makes this less likely

Standard HCM evaluation if diagnosis confirmed:

• Genetic testing for sarcomere gene mutations 1
• Family screening of first-degree relatives with echocardiography 3
• Risk stratification for sudden cardiac death
• Holter monitoring for ventricular arrhythmias

Treatment Considerations

If This is Acute MI:

• Standard acute coronary syndrome management
• Revascularization as indicated
• Dual antiplatelet therapy, statins, beta-blockers

If This is Infiltrative Disease:

• Cardiac sarcoidosis: Immunosuppression with corticosteroids ± methotrexate 2
• Amyloidosis: Disease-specific therapy (tafamidis for ATTR, chemotherapy for AL)
• Fabry disease: Enzyme replacement therapy

If This is True HCM with Systolic Dysfunction:

• Standard heart failure therapy: ACE inhibitors/ARBs, beta-blockers, diuretics
• Avoid septal reduction therapy: The 2024 guidelines state SRT is for obstructive HCM with preserved systolic function 3
• Consider ICD for primary prevention given high-risk features
• Evaluate for heart transplantation if refractory heart failure

Critical Pitfalls to Avoid

1. Do not assume this is typical HCM without excluding coronary disease and infiltrative processes
2. Do not perform septal reduction therapy (myectomy or alcohol ablation) in a patient with severely reduced systolic function—these procedures are contraindicated 3
3. Do not use negative inotropes (verapamil, disopyramide) if systolic function is severely reduced
4. Do not delay coronary angiography if any suspicion of acute coronary syndrome exists

Bottom Line

Proceed immediately to coronary angiography and cardiac MRI. The combination of asymmetric septal hypertrophy with severely reduced systolic function and segmental wall motion abnormality represents either acute MI, infiltrative disease, or a very rare presentation of end-stage HCM. Standard HCM management algorithms do not apply until alternative diagnoses are excluded 1.